Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Harvard Business School
Daiichi Sankyo
Queensland Health

Generated: November 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,013,556

« Back to Dashboard

Summary for Patent: 5,013,556

Title: Liposomes with enhanced circulation time
Abstract:A liposome composition which contains between 1-20 mole percent of an amphipathic lipid derivatized with a polyalkylether, as exemplified by phosphatidylethanolamine derivatized with polyethyleneglycol. The derivatized lipid enchances the circulation time of the liposomes severalfold, and this enhancement is achieved with either fluid or membrane-rigidifying liposome components. Also disclosed are methods for delivering a drug for slow release from the bloodstream, and for targeting a selected tissue or cells with liposomes, via the bloodstream.
Inventor(s): Woodle; Martin C. (Menlo Park, CA), Martin; Francis J. (San Francisco, CA), Yau-Young; Annie (Los Altos, CA), Redemann; Carl T. (Walnut Creek, CA)
Assignee: Liposome Technology, Inc. (Menlo Park, CA)
Application Number:07/425,224
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Delivery; Compound; Use;

No matches for this query

International Patent Family for Patent: 5,013,556

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria115401► Subscribe
Austria122229► Subscribe
Austria142483► Subscribe
Austria152614► Subscribe
Australia5323194► Subscribe
Australia642679► Subscribe
Australia6527294► Subscribe
Australia654120► Subscribe
Australia6637490► Subscribe
Australia6898291► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus